China Universal Asset Management Co. Ltd. Acquires 3,652 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)

China Universal Asset Management Co. Ltd. raised its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 65.4% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 9,232 shares of the company’s stock after buying an additional 3,652 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Axsome Therapeutics were worth $830,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in AXSM. Principal Financial Group Inc. increased its stake in shares of Axsome Therapeutics by 2.9% during the first quarter. Principal Financial Group Inc. now owns 9,773 shares of the company’s stock valued at $780,000 after buying an additional 276 shares during the period. Oak Ridge Investments LLC increased its stake in shares of Axsome Therapeutics by 2.7% during the first quarter. Oak Ridge Investments LLC now owns 15,930 shares of the company’s stock valued at $1,271,000 after buying an additional 413 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Axsome Therapeutics by 323.8% during the first quarter. BNP Paribas Financial Markets now owns 82,544 shares of the company’s stock valued at $6,587,000 after buying an additional 63,067 shares during the period. Janney Montgomery Scott LLC increased its stake in shares of Axsome Therapeutics by 9.5% during the first quarter. Janney Montgomery Scott LLC now owns 5,780 shares of the company’s stock valued at $461,000 after buying an additional 500 shares during the period. Finally, Mutual of America Capital Management LLC increased its stake in shares of Axsome Therapeutics by 20.4% during the first quarter. Mutual of America Capital Management LLC now owns 41,620 shares of the company’s stock valued at $3,321,000 after buying an additional 7,042 shares during the period. 81.49% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on AXSM shares. Bank of America raised Axsome Therapeutics from a “neutral” rating to a “buy” rating and boosted their target price for the company from $95.00 to $106.00 in a research note on Tuesday, August 6th. HC Wainwright reissued a “buy” rating and set a $180.00 target price on shares of Axsome Therapeutics in a research note on Thursday, September 5th. Royal Bank of Canada boosted their target price on Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a research note on Friday, October 4th. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 1st. Finally, UBS Group reduced their price target on Axsome Therapeutics from $107.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $124.64.

Axsome Therapeutics Trading Up 0.3 %

NASDAQ AXSM opened at $90.35 on Wednesday. Axsome Therapeutics, Inc. has a 12 month low of $55.02 and a 12 month high of $98.40. The stock has a market cap of $4.29 billion, a P/E ratio of -14.16 and a beta of 1.26. The stock’s fifty day moving average price is $90.09 and its 200-day moving average price is $82.34. The company has a current ratio of 2.48, a quick ratio of 2.40 and a debt-to-equity ratio of 1.77.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Monday, August 5th. The company reported ($1.24) EPS for the quarter, topping analysts’ consensus estimates of ($1.30) by $0.06. Axsome Therapeutics had a negative return on equity of 117.46% and a negative net margin of 105.85%. The firm had revenue of $87.17 million for the quarter, compared to analysts’ expectations of $84.53 million. As a group, equities analysts forecast that Axsome Therapeutics, Inc. will post -4.73 EPS for the current fiscal year.

Insider Activity

In other news, COO Mark L. Jacobson sold 47,739 shares of the company’s stock in a transaction on Friday, August 9th. The stock was sold at an average price of $84.26, for a total transaction of $4,022,488.14. Following the transaction, the chief operating officer now directly owns 5,783 shares of the company’s stock, valued at $487,275.58. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, Director Mark E. Saad sold 11,016 shares of the company’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the transaction, the director now directly owns 10,002 shares of the company’s stock, valued at $913,282.62. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Mark L. Jacobson sold 47,739 shares of the company’s stock in a transaction on Friday, August 9th. The shares were sold at an average price of $84.26, for a total value of $4,022,488.14. Following the transaction, the chief operating officer now directly owns 5,783 shares in the company, valued at approximately $487,275.58. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 22.40% of the company’s stock.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.